AbbVie R&D spending 2012-2021

This statistic illustrates the expenditure of AbbVie on research and development from 2012 to 2021. In 2021, AbbVie spent some 7.1 billion U.S. dollars on research and development. Abbot was a U.S.-based global pharmaceutical and healthcare products company, headquartered in Chicago, Illinois. In January 2013, Abbott was separated into two companies: Abbott Laboratories and AbbVie. Abbott Laboratories is now specialized on medical products, while AbbVie is responsible for research-based pharmaceuticals. On May 8, 2020, AbbVie completed the acquisition of Allergan plc.

AbbVie's research and development spending from 2012 to 2021 (in million U.S. dollars)

Characteristic	R&D spending in million U.S. dollars
2021	7,084
2020	6,557
2019	6,407
2018*	10,329
2017	5,007
2016	4,385
2015	4,285
2014	3,297
2013	2,855
2012	2,778

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

2022

More information

Region

Worldwide

Survey time period

2012 to 2021

Supplementary notes

* Research and development expenses in 2018 increased from 2017 principally due to a $5.1 billion intangible asset impairment charge related to IPR&D acquired as part of the 2016 Stemcentrx acquisition following the decision to stop enrollment in the TAHOE trial.